11 February 2020 - - US-based biotechnology company Magenta Therapeutics (NASDAQ: MGTA) has expanded its senior leadership with two new hires, Kristen Stants as chief people officer and Li Malmberg, Ph.D., as senior vice president, head of manufacturing, the company said.

Stants joins Magenta from Alexion Pharmaceuticals, where she served as Head of Talent Strategy, responsible for organizational development and talent acquisition to expand the company's therapeutic pipeline.

Prior to that, she led talent management and development strategy at Patheon Pharmaceuticals, in addition to 10 years at Biogen, where she held various leadership roles in executive development and organizational effectiveness.

Stants holds a Master of Industrial and Labor Relations with a concentration in Organizational Behavior from Cornell University and a Bachelor of Science in Psychology and Business from the University of Oregon.

Malmberg has more than 25 years of manufacturing experience, coming to Magenta from Celgene Corp., where she served as vice president, Head of Biologics Development and Manufacturing, responsible for the company's manufacturing development and biologics manufacturing organization and advanced more than 20 biologics molecule and launched one commercial product.

Prior to this role, Dr. Malmberg was director, Head of Process Sciences at Abbvie, Inc. where she built and led an organization of more than 80 scientists and engineers responsible for biologics drug development from preclinical to commercial launch. Previous roles include various leadership roles in R and D at Abbott Laboratories.

She holds a Ph.D. in Chemical Engineering from the University of Minnesota-Twin Cities; a Master of Science in Chemical Engineering from the University of Wisconsin-Madison; and a Bachelor of Science in Chemical Engineering from the University of Illinois at Urbana-Champaign.

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers.